 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 3 | 1/1 | 返回列表 |
| 查看: 1377 | 回復: 2 | |||
| 本帖產(chǎn)生 1 個 翻譯EPI ，點擊這里進行查看 | |||
zyfdxmc金蟲 (小有名氣)
|
[交流]
求助翻譯英文摘要三篇（英譯漢）每篇15個金幣
|
||
|
48 Care and follow-up of non-insulin treated diabetics in metropolitan France in 1998 Weill A. Ricordeau P. Vallier N. Bourrel R. Fender P. Allemand H. Diabetes and Metabolism (2000) 26:SUPPL. 6 (39-48). Date of Publication: 2000 The statistical analysis of French HealthCare's database allows a retrospective evaluation of the overall clinical care given to diabetics in the light of the guidelines (RBPC) promulgated by the National Agency of Health Accreditation and Evaluation (ANAES). This database contains no information on the stage of the disease process, the completeness of the clinical evaluation (neurological or foot examination) or the results of significant blood tests. We studied the follow-up care given to diabetics whom we were able to identify by isolating reimbursements for hypoglycemic agents using their corresponding drug codes. Considering the time needed for this new drug-coding system to become fully operational, the results can be extrapolated to the entire population of non-insulin treated diabetics. In 1998, almost all follow-up care was provided by general practitioners since only 5.5 % of the patients consulted an endocrinologist during the year studied. Blood sugar was generally monitored with fasting blood sugars rather than HbA1c which was only prescribed in 41.3 % of the patients during the final six months of the period under consideration. Screening and follow-up for degenerative complications were insufficient. Fewer than 40 % of the patients had received reimbursement for an ophtalmological consultation during the preceeding year and fewer than 30 % had an ambulatory resting EKG over the same time period. A certain number of factors were studied in order to determine if they were correlated to better clinical follow-up. The best follow-up was encountered in patients who had a consultation with an endocrinologist at least once during the year, those who were exonerated from co-payments (ALD 30) and finally, those aged between 40 and 59 years (at least with respect to appropriate laboratory tests). 49 Modalities of follow-up on non-insulin treated diabetics treated in metropolitan France in 1998 Weill A. Ricordeau P. Vallier N. Bourrel R. Fender P. Allemand H. Diabetes & metabolism (2000) 26 Suppl 6 (39-48) The statistical analysis of French HealthCare's database allows a retrospective evaluation of the overall clinical care given to diabetics in the light of the guidelines (RBPC) promulgated by the National Agency of Health Accreditation and Evaluation (ANAES). This database contains no information on the stage of the disease process, the completeness of the clinical evaluation (neurological or foot examination) or the results of significant blood tests. We studied the follow-up care given to diabetics whom we were able to identify by isolating reimbursements for hypoglycemic agents using their corresponding drug codes. Considering the time needed for this new drug-coding system to become fully operational, the results can be extrapolated to the entire population of non-insulin treated diabetics. In 1998, almost all follow-up care was provided by general practitioners since only 5.5 % of the patients consulted an endocrinologist during the year studied. Blood sugar was generally monitored with fasting blood sugars rather than HbA1c which was only prescribed in 41.3 % of the patients during the final six months of the period under consideration. Screening and follow-up for degenerative complications were insufficient. Fewer than 40 % of the patients had received reimbursement for an ophtalmological consultation during the preceeding year and fewer than 30 % had an ambulatory resting EKG over the same time period. A certain number of factors were studied in order to determine if they were correlated to better clinical follow-up. The best follow-up was encountered in patients who had a consultation with an endocrinologist at least once during the year, those who were exonerated from co-payments (ALD 30) and finally, those aged between 40 and 59 years (at least with respect to appropriate laboratory tests). 50 Clinical evaluation methods for new antimicrobial agents to treat respiratory infections: Report of the Committee for the Respiratory System, Japan Society of Chemotherapy Saito A. Miki F. Oizumi K. Rikitomi N. Watanabe A. Koga H. Niki Y. Kusano N. Journal of Infection and Chemotherapy (1999) 5:2 (110-123). Date of Publication: Jun 1999 The present report constitutes an attempt to improve and modify the existing clinical evaluation method for new antimicrobial agents to treat respiratory infections. One year ago, a general guideline on the clinical evaluation of antimicrobial agents to treat respiratory infections was drafted in Japanese, leaving scope for critical discussion, and this has been translated into English, as there were no major changes. In this report, respiratory infections have been discussed under the headings 'acute respiratory tract infection' and pneumonia and acute exacerbation of chronic pulmonary diseases. Standardized criteria were set for the assessment of severity of infection and effectiveness of the antimicrobial agent in question. Severity was evaluated on the basis of a combined assessment of the severity of infection and severity of the clinical condition of the patients. Clinical effectiveness of the antimicrobial agent used was evaluated on the basis of clinical outcome as well as micro- biological outcome of the trial. Body temperature, local pain, cough, change in sputum quality, peripheral white blood cell count, C-reactive protein level, and chest radiograph were used as the parameters for the evaluation. To maintain the quality of specimens to be examined, Geckler's classification of specimens was used. This report was constructed based on the analysis of large amounts of material collected over the years, incorporating internal and external factors concerning the present evaluation methods. The newly suggested standardized criteria for clinical evaluation of the new antimicrobial drugs are expected to be practiced properly hereupon and subjected to further improvement if necessary. |
回復此樓» 猜你喜歡
085600材料與化工調(diào)劑 324分
已經(jīng)有5人回復
-
344求調(diào)劑
已經(jīng)有6人回復
-
266求調(diào)劑
已經(jīng)有9人回復
-
化學工程321分求調(diào)劑
已經(jīng)有18人回復
-
314求調(diào)劑
已經(jīng)有8人回復
-
08工科 320總分 求調(diào)劑
已經(jīng)有5人回復
-
085601專碩，總分342求調(diào)劑，地區(qū)不限
已經(jīng)有5人回復
-
311求調(diào)劑
已經(jīng)有6人回復
-
化工學碩306求調(diào)劑
已經(jīng)有10人回復
-
286求調(diào)劑
已經(jīng)有8人回復
cam967
金蟲 (著名寫手)
- 翻譯EPI: 21
- 應助: 0 (幼兒園)
- 金幣: 1146.8
- 散金: 330
- 紅花: 2
- 帖子: 1082
- 在線: 268.7小時
- 蟲號: 549628
- 注冊: 2008-04-21
- 性別: GG
- 專業(yè): 高分子，納米，生物
2樓2010-05-29 17:37:21
noleg
金蟲 (小有名氣)
- 翻譯EPI: 52
- 應助: 0 (幼兒園)
- 貴賓: 0.005
- 金幣: 1423.7
- 帖子: 161
- 在線: 43.9小時
- 蟲號: 932452
- 注冊: 2009-12-23
- 性別: GG
zyfdxmc(金幣+15, 翻譯EPI+1):謝謝！ 2010-06-01 20:14:26
|
48 1998年法國大城市中非胰島素治療的糖尿病人的護理及復診/隨訪 Weill A. Ricordeau P. Vallier N. Bourrel R. Fender P. Allemand H. 糖尿病和新陳代謝 (2006) 26:SUPPL. 6(39-48). Date of Publication:2000 對法國健康護理中心數(shù)據(jù)庫的統(tǒng)計分析，使得我們可以對按照國家健康鑒定和評估署(ANAES)所頒布的指南(RBPC)對糖尿病患者的總體臨床護理進行追溯性評估。該數(shù)據(jù)庫并不包含有關(guān)疾病治療的階段、臨床評估(神經(jīng)學或足部檢查)的完整性、或者重要的血液檢查結(jié)果等方面的數(shù)據(jù)。我們研究了對糖尿病患者的后續(xù)護理。這些患者身份是通過甄別使用相應藥物代碼的低血糖藥物報銷單據(jù)來確認的�？紤]到該新型藥物編碼系統(tǒng)完全運行的時間，本研究結(jié)果可被外推至所有接受非胰島素治療的糖尿病患者。在所研究的1998年度，幾乎所有后續(xù)護理都是由全科醫(yī)師實施的，而僅有5.5%的患者向內(nèi)分泌專家進行咨詢。血糖主要通過禁食（空腹）血糖跟蹤監(jiān)測而非HbA1c，只是在所考慮周期的最后6個月中，也僅有41.3%的患者按醫(yī)囑進行HbA1c監(jiān)測。對退行性并發(fā)癥的甄別和隨訪不充分。上一年度少于40%的患者報銷了眼科咨詢費，而在同一時期少于30%做了非臥床靜止心電圖檢查。對一些因素進行了研究，以便確定它們是否與更佳的臨床復診相關(guān)。碰上最佳復診的是那些該 年度中至少一次咨詢過內(nèi)分泌專家的患者，那些幸免于支付共付醫(yī)療費(ALD 30)的患者，最后還有那些年齡在40至59年的患者（至少對于適宜的實驗室試驗是如此）。 |
3樓2010-05-30 23:59:02
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 zyfdxmc 的主題更新
| 3 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 08工科 320總分 求調(diào)劑 +5 | 梨花珞晚風 2026-03-17 | 5/250 |
|
|---|---|---|---|---|
|
[考研] 311求調(diào)劑 +11 | 冬十三 2026-03-15 | 12/600 |
|
|
|
[考研] 0703化學調(diào)劑 ，六級已過，有科研經(jīng)歷 +10 | 曦熙兮 2026-03-15 | 10/500 |
|
|
|
[考研] 265求調(diào)劑 +3 | 梁梁校校 2026-03-17 | 3/150 |
|
|
|
[考研] 268求調(diào)劑 +7 | 好運連綿不絕 2026-03-12 | 8/400 |
|
|
|
[考研] 326求調(diào)劑 +5 | 上岸的小葡 2026-03-15 | 6/300 |
|
|
|
[考研] 085601求調(diào)劑 +4 | Du.11 2026-03-16 | 4/200 |
|
|
|
[考研] 085600材料與化工求調(diào)劑 +5 | 緒幸與子 2026-03-17 | 5/250 |
|
|
|
[考研] 材料與化工專碩調(diào)劑 +5 | heming3743 2026-03-16 | 5/250 |
|
|
|
[考研] 275求調(diào)劑 +4 | 太陽花天天開心 2026-03-16 | 4/200 |
|
|
|
[考研] 274求調(diào)劑 +5 | 時間點 2026-03-13 | 5/250 |
|
|
|
[考研] 085600調(diào)劑 +5 | 漾漾123sun 2026-03-12 | 6/300 |
|
|
|
[考研] 0703化學調(diào)劑 290分有科研經(jīng)歷，論文在投 +7 | 膩膩gk 2026-03-14 | 7/350 |
|
|
|
[考研] 326求調(diào)劑 +3 | mlpqaz03 2026-03-15 | 3/150 |
|
|
|
[考研] 0856專碩279求調(diào)劑 +5 | 加油加油！? 2026-03-15 | 5/250 |
|
|
|
[考研] 085601材料工程315分求調(diào)劑 +3 | yang_0104 2026-03-15 | 3/150 |
|
|
|
[考研] 328求調(diào)劑 +3 | 5201314Lsy！ 2026-03-13 | 6/300 |
|
|
|
[考研] 281求調(diào)劑 +9 | Koxui 2026-03-12 | 11/550 |
|
|
|
[考研] 工科278分求調(diào)劑 +5 | 周慢熱啊 2026-03-12 | 7/350 |
|
|
|
[考研] 270求調(diào)劑 085600材料與化工專碩 +3 | YXCT 2026-03-11 | 3/150 |
|